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Background: Selexipag, an orally available, selective IP receptor agonist targeting the prostacyclin pathway, is chemically and 
pharmacologically distinct from prostanoids. The GRIPHON trial evaluated the long-term effect of selexipag on morbidity/mortality (M/M) as 
well as tolerability and safety in patients with pulmonary arterial hypertension (PAH).
methods: In this multicenter, double-blind, placebo-controlled, phase 3 study PAH patients (18-75 years) were randomized 1:1 to placebo 
or selexipag. Study drug was titrated to an individual highest tolerated dose (from 200 to 1600 µg b.i.d.). Stable background PAH therapy 
with endothelin receptor antagonists (ERA) and/or phosphodiesterase-5 inhibitors (PDE-5i) was allowed. The primary endpoint was the 
time from randomization to first M/M event up to the end of treatment, defined as either disease progression (based on 15% decrease in 
6-minute walk, and either worsening of functional class [FC] or need for additional PAH therapy), hospitalization for PAH worsening, PAH 
worsening (need for atrial septostomy or lung transplant; initiation of parenteral prostanoids or chronic O2 therapy), or all-cause death.
results: 1156 patients were randomized to placebo (n=582) or selexipag (n=574); 20% were PAH therapy naive, 47% were on 
monotherapy (ERA or PDE-5i) and 33% on combination therapy (ERA and PDE-5i) at baseline. Mean duration of selexipag and placebo 
treatment was 76.4±50.45 and 71.2±48.32 weeks, respectively. Selexipag reduced the risk of M/M events vs placebo (log-rank p<0.0001) 
by 40% (HR 0.60; 99% CI: 0.46, 0.78). The treatment effect was consistent across age, gender, etiology, baseline FC and background 
PAH therapy sub-groups. The most frequent adverse events (selexipag >3% over placebo) were headache, diarrhea, nausea, jaw pain, 
myalgias, pain in extremity, flushing and arthralgia, consistent with prostacyclin effects.
conclusion:  Selexipag demonstrated a significant effect on the time to first M/M event in PAH patients and had an acceptable safety 
profile. The treatment effect was observed irrespective of background treatment with ERA, PDE-5i, or both. Results from GRIPHON 
indicate selexipag is an efficacious PAH treatment.
